132 related articles for article (PubMed ID: 2362192)
1. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.
Colcher D; Milenic DE; Ferroni P; Carrasquillo JA; Reynolds JC; Roselli M; Larson SM; Schlom J
J Nucl Med; 1990 Jul; 31(7):1133-42. PubMed ID: 2362192
[TBL] [Abstract][Full Text] [Related]
2. In vivo fate of monoclonal antibody B72.3.
Halpern SE
J Nucl Med; 1990 Jul; 31(7):1143-6. PubMed ID: 2362193
[No Abstract] [Full Text] [Related]
3. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
Colcher D; Milenic D; Roselli M; Raubitschek A; Yarranton G; King D; Adair J; Whittle N; Bodmer M; Schlom J
Cancer Res; 1989 Apr; 49(7):1738-45. PubMed ID: 2924317
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.
Roselli M; Hitchcock CL; Molinolo A; Milenic DE; Colcher D; Martin EW; Hinkle GH; Schlom J
Anticancer Res; 1995; 15(3):975-84. PubMed ID: 7645989
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
6. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
7. The use of monoclonal antibody B72.3 in the management of gynecologic malignancies.
Simpson J; Schlom J
Yale J Biol Med; 1988; 61(4):351-66. PubMed ID: 3055701
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.
Khazaeli MB; Saleh MN; Liu TP; Meredith RF; Wheeler RH; Baker TS; King D; Secher D; Allen L; Rogers K
Cancer Res; 1991 Oct; 51(20):5461-6. PubMed ID: 1913665
[TBL] [Abstract][Full Text] [Related]
9. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture.
Johnston WW
Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301
[TBL] [Abstract][Full Text] [Related]
10. Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay.
Guadagni F; Roselli M; Cosimelli M; Spila A; Cavaliere F; Tedesco M; Arcuri R; Abbolito MR; Casale V; Pericoli MN; Vecchione A; Casciani CU; Greiner JW; Schlom J
Cancer Res; 1996 Nov; 56(22):5293-8. PubMed ID: 8912871
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
Muraro R; Kuroki M; Wunderlich D; Poole DJ; Colcher D; Thor A; Greiner JW; Simpson JF; Molinolo A; Noguchi P
Cancer Res; 1988 Aug; 48(16):4588-96. PubMed ID: 3396010
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas.
Katari RS; Fernsten PD; Schlom J
Cancer Res; 1990 Aug; 50(16):4885-90. PubMed ID: 2379152
[TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA
Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1.
Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N
Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816
[TBL] [Abstract][Full Text] [Related]
15. Decreased production of anti-mouse antibody after administration of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate to human.
Yata Y; Otsuji E; Okamoto K; Tsuruta H; Kobayashi S; Toma A; Yamagishi H
Hepatogastroenterology; 2003; 50(49):80-4. PubMed ID: 12629996
[TBL] [Abstract][Full Text] [Related]
16. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
[TBL] [Abstract][Full Text] [Related]
18. Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody.
Stewart JS; Sivolapenko GB; Hird V; Davies KA; Walport M; Ritter MA; Epenetos AA
Cancer Res; 1990 Feb; 50(3):563-7. PubMed ID: 2297697
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.
Colcher D; Minelli MF; Roselli M; Muraro R; Simpson-Milenic D; Schlom J
Cancer Res; 1988 Aug; 48(16):4597-603. PubMed ID: 3396011
[TBL] [Abstract][Full Text] [Related]
20. Long-term persistence of human anti-murine antibody responses following radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphoma patients using 131I-T101.
Goldman-Leikin RE; Kaplan EH; Zimmer AM; Kazikiewicz J; Manzel LJ; Rosen ST
Exp Hematol; 1988 Nov; 16(10):861-4. PubMed ID: 3262528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]